12:00 AM
 | 
Jun 20, 2016
 |  BC Week In Review  |  Company News  |  Deals

Otsuka Pharmaceutical, Acucela deal

Otsuka terminated deals with Acucela to co-develop and co-commercialize Acucela’s emixustat ( ACU-4429) and Otsuka’s OPA-6566. The emixustat deal was signed in 2008 and granted Otsuka co-development rights in North America and exclusive...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >